Neural Noise

NeuCyber

3 min read

  • NeuCyber is described in trade/aggregator coverage as a China-backed brain–computer interface company.1
  • A March 2026 Inshorts headline claims NeuCyber said it is about three years behind Neuralink and frames China as the “second country” to begin human trials of implantable BCI—claims that should be treated as unverified without primary regulatory/clinical documentation in the supplied excerpt.1
  • An IndexBox “news and statistics” style note titles China’s BCI progress around NeuCyber’s lag and state-backed development, explicitly flagged as secondary research requiring scrutiny of methodology and provenance.2 1
  • NeuCyber NeuroTech was spun out in 2023 from the Chinese Institute for Brain Research, Beijing (CIBR), which itself was founded in 2018 via a collaboration between the Beijing municipal government and local universities; it is a subsidiary of the state-owned Zhongguancun Development Corporation (>$1.2 billion in 2023 revenue) and has received approximately 200 million yuan (~$29 million) in Beijing government funding.2
  • The flagship product Beinao-1 (NeuCyber Matrix BCI System) is a semi-invasive, wireless device: a flexible electrode array with 128 channels sits on the brain’s outer membrane (epidural, above the dura) rather than penetrating cortical tissue, achieving the world’s highest reported signal throughput for a wireless, fully implanted, semi-invasive BCI system.3
  • By June 2026, 16 patients have received Beinao-1 implants across 16 medical centers in China; the system has accumulated >55,000 hours of safe operation and enabled motor rehabilitation and robotic arm control; the longest single implantation period exceeds one year.3
  • Beinao-1 entered registered clinical trials (formal regulatory-track) in June 2026 after ~30 implants in investigator-initiated trials; the team targets enrollment completion in 2026 and application for a medical device registration certificate in 2027.3
  • The more advanced Beinao-2 (NeuCyber Array BCI System) uses 512-channel, fully implantable wireless high-throughput flexible microelectrode arrays that penetrate brain tissue to capture individual neuronal firing; it completed large animal testing and is scheduled to begin clinical validation by end of 2026.3
  • In March 2026, China’s National Medical Products Administration (NMPA) separately approved Neuracle Technology’s NEO device—a coin-sized semi-invasive BCI for spinal cord injury patients—as the world’s first invasive BCI cleared for commercial use outside clinical trials; China has added it to national health insurance.4
  • BCI was designated a “future industry” in China’s 15th Five-Year Plan (2026–2030) alongside a $165 million national brain science fund, cementing state support for the sector.5
  • NeuCyber’s rotating CEO Li Yuan acknowledged a ~3-year lag behind Neuralink on the most invasive product tier (Beinao-2 vs. Neuralink N1), but noted Beinao-1’s semi-invasive approach could yield faster regulatory clearance; the company targets making BCIs available domestically within 2–3 years of receiving full approval from China’s health commission, medical insurance authorities, and NMPA.4

Footnotes

  1. https://english.aawsat.com/varieties/5253495-beijing-backed-brain-chip-firm-says-it-3-years-behind-musks-neuralink ↩ ↩2 ↩3

  2. https://www.reuters.com/business/healthcare-pharmaceuticals/chinese-brain-chip-project-speeds-up-human-trials-after-first-success-2025-03-31/ ↩ ↩2

  3. https://global.chinadaily.com.cn/a/202606/15/WS6a2fc5cba310986e2b460147.html ↩ ↩2 ↩3 ↩4

  4. https://www.bloomberg.com/news/articles/2026-03-13/china-approves-first-brain-implant-for-commercial-use ↩ ↩2

  5. https://www.youtube.com/watch?v=okxvk08uAwo ↩

Graph View